Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.
This review analyses a recent advance in diabetes pharmacotherapeutics: the combination of insulin and glucagon-like peptide 1 receptor agonists (GLP 1 RA). It describes the rationale for such a combination, and discusses the impact of such therapy on glycaemic control. The paper also assesses other benefits of the combination, and provides a practical framework for pragmatic, rational use of this treatment.